Clinical Trials
152 trialsNCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01174121 2026-05-22
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT02849496 2026-05-22
Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03412877 2026-05-22
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06195306 2026-05-20
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04550494 2026-05-13
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05941520 2026-05-13
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06184750 2026-05-13
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT02311933 2026-05-01
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02498613 2026-05-01
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02883062 2026-04-13
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02595905 2026-04-08
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
Phase 2 Completed
NCT00861705 2025-09-30
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01149083 2025-08-15
Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01349959 2025-04-27
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT04102436 2024-03-12
Non-Viral TCR Gene Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT00096434 2024-03-07
Sorafenib in Treating Patients With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01142401 2023-11-27
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01622868 2023-10-17
Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02598557 2023-08-22
Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02203513 2022-09-10
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01849250 2021-12-28
Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors
National Cancer Institute (NCI)
Phase 2 Completed
NCT01967823 2021-03-24
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00684983 2020-03-24
Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00376688 2020-02-24
Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00262834 2020-02-19
Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00602043 2020-02-19
F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01624090 2019-12-30
Mithramycin for Lung, Esophagus, and Other Chest Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00978250 2019-12-27
A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03300843 2019-12-13
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01679743 2019-11-15
GRN1005 for Brain Metastases From Breast or Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT01964924 2019-09-20
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01277757 2018-12-19
Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00082810 2018-11-01
Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00509587 2018-08-08
Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01776008 2018-05-08
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00118157 2017-12-04
Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
National Cancer Institute (NCI)
Phase 2 Completed
NCT01688609 2017-09-11
Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01319539 2017-08-30
MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00054132 2017-07-24
Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00016549 2017-07-02
Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00092950 2017-07-02
Exercise in Women at Risk for Breast Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01306032 2017-04-26
Phase II ABT-888 With Cyclophosphamide
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01151449 2017-04-11
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00290758 2017-02-08
Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00096109 2017-01-16
Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00572728 2016-12-30
Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01339000 2016-06-22
Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01575522 2016-03-21
Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00244881 2015-12-07
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
National Cancer Institute (NCI)
Phase 2 Completed